Industry Briefs: Apr. 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor.
Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe.
Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate.
Pharmatek has added to its liquid encapsulation capabilities.
Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.
Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology.
Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly.
People News
Hospira has named John B. Elliot senior vice-president of operations.
Penn Pharma has appointed Jerome Detreille as senior director of new business development.
Michael A. Griffith has been appointed to Repligen’s board of directors.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
